An interventional study of Dynamic cMAP and Direct cMAP in Obstructive Sleep Apnea, sponsored by NovaResp Technologies Inc. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by NovaResp Technologies Inc · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to identify which settings of proactive therapy work best in OSA patients who regularly adhere to PAP therapy at home. The main question(s) it aims to answer are:
Nights in which conventional APAP was used and nights in which proactive therapy was used to see which settings treated patients most effectively.
This is a single-arm, single-blinded, non-randomised, within-subject study on patients diagnosed with obstructive sleep apnea who regularly adhere to PAP therapy. Data collection will span 6 to 8 months for each participant at home. Participants will use two of three modified PAP devices for at least 12 weeks each. Each device period is divided into 7-day therapy blocks, starting with conventional APAP therapy (i.e., the participant's regular therapy but on the modified device) to establish a baseline, followed by blocks of proactive therapy, with a repeat APAP block midway. Proactive therapy is delivered in two modes: a) Dynamic cMAP®, where AI predictions guide adjustable therapy settings, and b) Direct cMAP®, where AI sets the therapy pressure directly. Therapy settings may be refined between blocks as data are collected, and pressure is always limited by independent safety limits. Participants will be blinded to the therapy they are receiving. Data will be collected by the modified PAP device and at-home sleep apnea test ring.
2,266 studies on the registry are indexed under Sleep Apnea, Obstructive; 468 are open to participants now.
This study's planned enrollment of 50 is close to the median of 53 across 1,492 interventional studies indexed under Sleep Apnea, Obstructive.
Browse Sleep Apnea, Obstructive studies →NovaResp Technologies Inc is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
On each of two PAP devices, patients will undergo conventional APAP therapy first, followed by blocks of proactive therapy, with a repeat APAP block midway.
Device: Dynamic cMAP · Device: Direct cMAP
Uses AI to make predictions of future apneic events. A deterministic algorithm uses output predictions to determine pressure.
Uses AI to directly determine the therapy pressure to prevent future apneic events
Apnea-Hypopnea Index (AHI)
Calculated as the mean number of apnea and hypopnea events throughout the night, in events/hr. AHI= total number of apnea events+ total number of hypopnea events/total sleep time (hours). Normal: \<5 events per hour Mild Sleep Apnea: 5 to 14.9 events per hour Moderate Sleep Apnea: 15 to 29.9 events per hour Severe Sleep Apnea: \>30 events per hour
Time frame: 6-8 months
Oxygen Saturation
Calculated as the mean blood oxygen saturation throughout the night, in percentage. This is completed by using an FDA approved wearable ring that uses cardiopulmonary coupling for the measurement of blood oxygen saturation. 95-100% is healthy for adults 90%-94% is low/borderline \<90% Clinically low/Hypoxemia
Time frame: 6-8 months
Sleep quality
Sleep quality is calculated using heart rate variability (HRV), sleep efficiency, and sleep fragmentation which is measured throughout the night. These measurements are calculated by using an FDA approved wearable ring that uses cardiopulmonary coupling, resulting in the measurement of sleep quality. Sleep quality is measure in percentage.
Time frame: 6-8 months
Mask Pressure
Calculated as the mean pressure throughout the night.
Time frame: 6-8 months
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NovaResp Technologies Inc